Aptose Biosciences Files Second Amendment to Going-Private Transaction Statement for Hanmi Acquisition
APTOF has more than doubled off its 52-week low of $0.636 on light trading volume (0.1× avg).
Summary
Aptose Biosciences filed an amendment to its Rule 13e-3 transaction statement, providing updated disclosures for its acquisition by Hanmi Pharmaceutical Co. Ltd. at C$2.41 per share, leading to delisting.
Key Events · M&A and Partnerships · APTOF
-
Updated Going-Private Disclosure
Aptose Biosciences filed Amendment No. 2 to its SC 13E3, updating disclosures for the acquisition by Hanmi Pharmaceutical Co. Ltd. This follows the initial SC 13E3 filed on January 15, 2026, and a previous amendment on February 9, 2026.
-
Acquisition Terms Confirmed
The transaction involves HS North America Ltd. acquiring all outstanding common shares for C$2.41 (approximately USD $1.71) per share, a slight premium to the current stock price.
-
Delisting Imminent
Upon completion, Aptose will become a private entity, and its shares will be delisted from the Toronto Stock Exchange and OTC Markets.
-
Board Recommendation
The Board of Directors unanimously recommends shareholders approve the arrangement, supported by a fairness opinion from Locust Walk Securities, LLC.
Analysis · APTOF · Life Sciences
This filing, Amendment No. 2 to the SC 13E3, provides updated legal and financial disclosures in connection with the proposed acquisition of Aptose Biosciences by Hanmi Pharmaceutical Co. Ltd. It incorporates by reference the concurrently filed definitive proxy statement, signaling a critical step towards the completion of the going-private transaction. The acquisition, priced at C$2.41 (approximately USD $1.71) per common share, will result in Aptose becoming a wholly-owned subsidiary and its shares being delisted from public exchanges. The board, based on a fairness opinion, unanimously recommends shareholders approve the arrangement.
At the time of this filing, APTOF was trading at $1.67 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.64 to $232.83. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.